Gerds Aaron T, Appelbaum Frederick R
University of Washington School of Medicine, Seattle, Washington 98109-1024, USA.
Clin Adv Hematol Oncol. 2012 Oct;10(10):655-62.
In 2007, a group of experts charged by the American Society for Blood and Marrow Transplantation critically reviewed the available literature and summarized the indications for allogeneic hematopoietic cell transplantation versus chemotherapy in adults with acute myeloid leukemia. Much of the resulting position statement was based on studies conducted nearly 2 decades ago, and may not accurately represent current treatment. As a result of advances in both therapeutic regimens and supportive care, a number of recent studies have demonstrated clear and consistent improvements in the outcomes of patients receiving chemotherapy and allogeneic hematopoietic cell transplantation. In addition, prognostic accuracy has improved with the identification of mutations not detected by traditional cytogenetics. With these advancements in prognostic accuracy and treatment, it is now appropriate to revisit the indications for transplantation versus chemotherapy.
2007年,美国血液和骨髓移植学会委托一组专家对现有文献进行了严格审查,并总结了成人急性髓系白血病患者接受异基因造血细胞移植与化疗的指征。由此产生的立场声明大部分基于近20年前进行的研究,可能无法准确反映当前的治疗情况。由于治疗方案和支持性护理方面的进展,最近的一些研究表明,接受化疗和异基因造血细胞移植的患者的治疗结果有明显且一致的改善。此外,随着传统细胞遗传学未检测到的突变的发现,预后准确性有所提高。随着预后准确性和治疗方面的这些进展,现在重新审视移植与化疗的指征是合适的。